Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Henk M. Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, Bronno van der Holt, Hans Martin, Rene Barge, Uta Bertsch, Jana Schlenzka, Gerard M. J. Bos, Sandra Croockewit, Sonja Zweegman, Iris Breitkreuz, Peter Joosten, Christof Scheid, Marinus van Marwijk-Kooy, Hans-Juergen Salwender, Marinus H. J. van Oers, Ron Schaafsma, Ralph Naumann, Harm SinnigeIgor Blau, Gregor Verhoef, Okke de Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, Hartmut Goldschmidt, Pieter Sonneveldbronno Van Der Holt

Research output: Contribution to journalArticleAcademicpeer-review

132 Citations (Scopus)


In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p <0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p <0.001). CTC grade 3-4 adverse events were similar in both arms
Original languageEnglish
Pages (from-to)124-127
Number of pages4
Issue number1
Publication statusPublished - Jan 2008


  • Thalidomide
  • Untreated multiple myeloma

Cite this